VL-2397

Star0

DB17796InvestigationalSmall molecule

VL-2397: Overview.

Formula / weight: C₄₀H₅₉AlN₁₀O₁₃ · 914.951 g/mol (avg)
Also known as: Cyclo(-asn-leu-d-phe-al((n5-acetyl-n5-hydroxy-orn)-(n5-acetyl-n5-hydroxy-orn)-(n5-hydroxy-orn))-) . al(iii) · Cyclo(l-asparaginyl-l-leucyl-d-phenylalanyl-n5-acetyl-n5-hydroxy-l-ornithyl-n5-acetyl-n5-hydroxy-l-ornithyl-n5-acetyl-n5-hydroxy-l-ornithyl), aluminum salt (1:1) · Cyclo{-asn-leu-d-phe-al[(N5-acetyl-N5-hydroxy-orn)-(N5-acetyl-N5-hydroxy-orn)-(N5-hydroxy-orn)]-} . Al(III)
Code names: ASP-2397 · VL-2397

Resolves to

Compound

UNIIE39B3691TDCAS1186200-57-6

Structure

InChIKeyNRHTWBFQTMOOKS-FELWXBABSA-NSMILES

[Al+3].CC(C)C[C@@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCN([O-])C(C)=O)NC(=O)[C@H](CCCN([O-])C(C)=O)NC(=O)[C@H](CCCN([O-])C(C)=O)NC(=O)[C@@H](CC2=CC=CC=C2)NC1=O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of VL-2397, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account